Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
about
The molecular rationale of Src inhibition in colorectal carcinomasPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesTargeting Src family kinases in anti-cancer therapies: turning promise into triumphCIViC databaseNovel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of AssaysRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsEpidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer.Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer.Gene profiling of MTA1 identifies novel gene targets and functions.Protein mislocalization: mechanisms, functions and clinical applications in cancer.Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumoursPhase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives.KRAS mutant colorectal tumors: past and presentPterostilbine, an active component of blueberries, sensitizes colon cancer cells to 5-fluorouracil cytotoxicity.ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaSym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabDasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation.Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer.Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer.Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Emerging EGFR antagonists for breast cancer.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma.Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.Integrating network reconstruction with mechanistic modeling to predict cancer therapies.Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.Novel therapeutic approaches in chondrosarcoma.Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer.
P2860
Q26853018-C16A0AE0-1988-444A-A060-5FAB0EB80491Q27015224-D277767D-7273-48E4-A7C1-39BC045FDA1AQ27025646-9A661F0F-B931-4382-A5E7-EADF4B1C1F2DQ27612411-06997BC7-43CD-4B92-980F-E6729B231C9AQ28546583-3DBADF4C-30B5-4FAA-83AC-BA9DD5ED1CDFQ28730438-4172C620-0BEE-4C4F-AE02-0F94F436CECDQ30412086-D834C741-66B2-417A-8755-ADF2EA9F4672Q33556004-5F223BF0-DD6A-4825-9F3D-C922110D4E07Q33576236-F11CC271-DED3-46D5-AF45-690110F0CD6CQ33580500-1377B556-D7CA-4117-882E-C2C9EA4C432CQ33588163-21B7CF77-2429-4066-9D7A-13A3FBF4E2DCQ33833747-15BA0FA6-2B70-4B21-BF4C-E95371905C85Q34076405-1E298053-0127-423D-99C9-116D7E0C6BD8Q34283737-CBFC10D1-5191-474C-910D-28FD43D78B17Q34480200-510F7360-0528-46C7-ABFA-77ABF9E480CCQ34635002-4DB936B2-9091-4D4F-9E94-07ECD4E42A47Q35001415-7D304CED-F0B7-47DF-B02E-29C087B728DAQ35144330-67B85AEC-CF87-4FDE-816C-218EA98AE715Q35569418-9F936E40-05CC-4969-AC01-F0CFACFE19C4Q35646234-430DC9AD-AD52-492B-9617-FF79BCE19DB8Q36100844-90B8684E-C531-480F-9518-FAE2251BFADAQ36168444-76292916-C89D-450B-9636-82345C937840Q36662230-FAA48CCA-901F-41A8-BCEE-52D977A4E6ECQ36949546-9AADBDA0-CE49-4F96-A11D-DD9A4044A301Q37285565-6AD37767-FAE4-4D38-A894-254C6F8C941DQ37362851-A726A1CF-6740-4509-92C2-1C5C16361C7FQ37581999-7208F01C-328A-4B77-8141-5C65B23272D1Q37706510-BBB331E6-20DE-43AD-9101-F47F97DE0676Q38002127-12A67CF7-4D50-4818-88E2-A55C09553D05Q38031834-84FD73DD-2DD0-4EBB-90C2-3C74D60A174FQ38090584-A0F842A9-C649-4D87-931E-9F582AB150FEQ38166233-78FCCEFB-DB0D-4B0D-AD78-C0019ED50910Q38211951-7E39A8D3-CF71-44E8-BA68-F8B2177BB188Q38390840-E29DF86D-B77F-4E3B-AB36-FC4EA9F0F1C6Q38430692-B8473ED2-50E6-4504-9463-7B1E4E52F006Q38718304-788B2949-2D2D-4A0A-917E-C63A8426D85AQ38729295-B92DABF4-DD32-4AD0-A241-7CD0D9A80535Q38757863-95C282BD-9FE8-4591-962A-0A129908F5E0Q38764510-52F3EDAE-1415-418F-9808-A37B97FBACE6Q38775314-07302A7E-A69B-4CE4-A8B2-97662C72F286
P2860
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@ast
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@en
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
@nl
type
label
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@ast
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@en
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
@nl
altLabel
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@en
prefLabel
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@ast
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@en
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
@nl
P2093
P2860
P3181
P356
P1433
P1476
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
@en
P2093
D A Campbell
D L Wheeler
E A Armstrong
P2860
P2888
P304
P3181
P356
10.1038/ONC.2010.430
P407
P577
2011-02-03T00:00:00Z
P5875
P6179
1051944491